Your browser doesn't support javascript.
Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
Mangia, Alessandra; Cenderello, Giovanni; Verucchi, Gabriella; Ciancio, Alessia; Fontana, Andrea; Piazzolla, Valeria; Minerva, Nicola; Squillante, Maria Maddalena; Copetti, Massimiliano.
  • Mangia A; Liver Unit, Department of Medical Sciences, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo 71013, Italy. a.mangia@tin.it.
  • Cenderello G; Department of Infectious Disease, ASL1 Imperiese, Sanremo 18038, Italy.
  • Verucchi G; Department of Infectious Disease, University of Bologna, Bologna 40138, Italy.
  • Ciancio A; Department of Gastroenterology, University of Turin, Torino 10156, Italy.
  • Fontana A; Department of Biostatistics, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo 71013, Italy.
  • Piazzolla V; Liver Unit, Department of Medical Sciences, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo 71013, Italy.
  • Minerva N; Department of Internal Medicine, Ospedale Bonomo, Andria 76123, Italy.
  • Squillante MM; Liver Unit, Department of Medical Sciences, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo 71013, Italy.
  • Copetti M; Department of Biostatistics, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo 71013, Italy.
World J Clin Cases ; 8(22): 5831-5834, 2020 Nov 26.
Article in English | MEDLINE | ID: covidwho-994300
ABSTRACT
Liver injury has been reported in coronavirus disease 2019 (COVID-19) cases but the impact of pre-existing liver damage and related etiology have not been completely elucidated. Our research interests include the potential reciprocal influence of COVID-19 and pre-existing liver damage related to hepatitis C virus (HCV) infection, in particular. To this end, we have evaluated three cohorts of patients admitted at three Italian hospitals during the coronavirus pandemic; these included 332 patients with COVID-19 and 1527 patients with HCV who were from established real-world antiviral treatment study cohorts (sofosbuvir/velpatasvir), with either liver disease (various severities; n = 1319) or cirrhosis (n = 208). Among the COVID-19 patients, 10 had cirrhosis (3%), including 7 of metabolic origin and 3 of viral origin. Mortality among the COVID-19 patients was 27.1%, with 70% of those with cirrhosis of metabolic etiology having died. Cirrhosis, older age, low white blood cell count and lymphocyte count being identified as risk predictors of death [odds ratio (OR) = 13.7, 95% confidence interval (CI) 2.59-83.01, P = 0.006; OR = 1.05, 95%CI 1.03-1.08, P = 0.0001; OR = 1.09, 95%CI 1.36-1.16, P = 0.001; OR = 0.61, 95%CI 0.39-0.93, P = 0.023, respectively]. In the two cohorts of HCV patients, COVID-19 diagnosis was made in 0.07% of those with liver disease and 1% of those with cirrhosis. Thus, the prevalence of HCV antibodies among COVID-19-infected patients was comparable to that currently reported for the general population in Italy. Amongst the COVID-19 patients, pre-existing metabolic cirrhosis appears to be associated with higher mortality, while HCV antibodies may be suggestive of "protection" against COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Etiology study / Experimental Studies / Observational study / Prognostic study Language: English Journal: World J Clin Cases Year: 2020 Document Type: Article Affiliation country: Wjcc.v8.i22.5831

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Etiology study / Experimental Studies / Observational study / Prognostic study Language: English Journal: World J Clin Cases Year: 2020 Document Type: Article Affiliation country: Wjcc.v8.i22.5831